RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REGENXBIO Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$7.15+0.23 (+3.25%)
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
REGENXBIO Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and royalty [Member] | $159.68M | $74.31M | $156.27M | $149.91M | $150.28M | $153.67M | $81.96M | $83.39M | $88.32M | $86.45M | $90.24M | $99.37M | 91.5% | +6.3% |
| Zolgensma Royalties [Member] | $53.62M | $70.29M | $82.54M | $79.66M | $79.94M | $83.28M | $81.51M | $82.71M | $87.21M | $84.41M | $85.32M | $90.24M | 30.7% | -32.9% |
| Service [Member] | $14.80M | $13.51M | $14.17M | $11.41M | $5.50M | $3.05M | $1.37M | – | – | – | – | – | 8.5% | +169.2% |
| Total Service Revenue [Member] | $14.80M | $13.51M | $14.17M | $11.41M | $5.50M | $3.05M | $1.37M | – | – | – | – | – | 8.5% | +169.2% |
| Nippon Shinyaku Services [Member] | $12.06M | $11.06M | $11.82M | – | – | – | – | – | – | – | – | – | 6.9% | – |
| Other [Member] | $2.74M | $2.46M | $2.35M | $985.00K | $1.00M | $1.28M | $1.37M | – | – | – | – | – | 1.6% | +172.8% |
| Nippon Shinyaku Licenses [Member] | – | – | $72.90M | – | – | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Regenxbio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.